LivaNova (NASDAQ:LIVN) Issues Earnings Results

LivaNova (NASDAQ:LIVN) announced its quarterly earnings results on Wednesday. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06, FiscalAI reports. The company had revenue of $360.90 million during the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 15.98% and a negative net margin of 16.12%.The firm’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.81 earnings per share. LivaNova updated its FY 2026 guidance to 4.150-4.250 EPS.

Here are the key takeaways from LivaNova’s conference call:

• The company reported double-digit organic revenue growth and 150 basis points of adjusted operating margin expansion in 2025, with strong cash generation and a 2026 revenue guide of +6% to +7% consistent with its Investor Day framework.
• LivaNova advanced its obstructive sleep apnea (OSA) program with a planned PMA approval for the clinical device in H1 2026, a follow-on MRI-compatible supplement and a commercial rollout targeting 2027, while highlighting the OSPREY RCT and the PolySync algorithm that management says can convert many non-responders.
• Epilepsy benefits from two near-term tailwinds: the CORE‑VNS clinical data
• Near‑term risks include third‑party component constraints for oxygenators, higher capital and R&D spend (2026 capex guidance ~$120M) to scale manufacturing and advance OSA, modest tariff exposure, and a reserved SNIA-related cash obligation (~$400M potential Q3 payment) that management says remains the company’s best estimate of the liability.

LivaNova Stock Up 1.7%

NASDAQ:LIVN traded up $1.16 on Wednesday, reaching $70.21. The stock had a trading volume of 996,657 shares, compared to its average volume of 698,878. The company has a 50-day moving average of $64.26 and a 200 day moving average of $58.73. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The stock has a market cap of $3.83 billion, a P/E ratio of -17.57 and a beta of 0.97. LivaNova has a 12-month low of $32.48 and a 12-month high of $70.78.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Barclays raised their price target on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a report on Friday, January 9th. Mizuho raised their target price on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Stifel Nicolaus lifted their target price on shares of LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Needham & Company LLC increased their price target on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday. Finally, KeyCorp began coverage on LivaNova in a research note on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $73.00.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC raised its stake in LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after acquiring an additional 544,033 shares during the period. Wellington Management Group LLP grew its holdings in shares of LivaNova by 83.5% during the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after purchasing an additional 496,165 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of LivaNova by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company’s stock worth $110,014,000 after purchasing an additional 66,755 shares during the period. Finally, Invesco Ltd. raised its position in shares of LivaNova by 4.5% during the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after purchasing an additional 47,323 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Key LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 results beat consensus: LivaNova reported $0.86 EPS vs. $0.80 expected and revenue of $360.9M vs. $354.3M expected; revenue was up ~12% year-over-year, and management provided supporting materials (press release, slide deck, conference call). MarketBeat — Earnings and Call
• Positive Sentiment: Upgrade and higher price target: Needham raised its price target from $64 to $81 and reiterated a Buy rating — a notable analyst endorsement that implies additional upside from current levels. Benzinga — Needham Price Target Raise
• Positive Sentiment: Raised FY‑2026 EPS guidance: LivaNova set full‑year EPS guidance of $4.15–$4.25 vs. consensus ~$3.90, signaling better-than-expected margin or growth assumptions for 2026; revenue guidance was affirmed near consensus. This outlook is the primary driver for the positive re-rating. BusinessWire — Q4 Results & 2026 Guidance
• Neutral Sentiment: Analyst/press discussion on reimbursement and growth drivers: Coverage (Investing.com) explores whether reimbursement gains can sustain growth — a potential tailwind but with execution and payor dynamics to watch. Investing.com — Reimbursement Analysis
• Neutral Sentiment: Strategic partnership coverage: Reporting (Yahoo Finance) highlights a data partnership with Orrum that could reshape the cardiac-care narrative — promising for long‑term positioning but speculative near term. Yahoo Finance — Data Partnership

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Featured Stories

• Five stocks we like better than LivaNova
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• This makes me furious
• Buy this Gold Stock Before May 2026
• What a Former CIA Agent Knows About the Coming Collapse